More articles from Myeloproliferative Disorders

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
Georg Greiner, Michael Gurbisz, Franz Ratzinger, Nadine Witzeneder, Svenja Verena Class, Gregor Eisenwort, Ingrid Simonitsch-Klupp, Harald Esterbauer, Matthias Mayerhofer, Leonhard Müllauer, Wolfgang R. Sperr, Peter Valent, Gregor Hoermann

Haematologica Apr 2019, haematol.2019.217950; DOI: 10.3324/haematol.2019.217950
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
Gaurav Goyal, Aishwarya Ravindran, Jason R. Young, Mithun V. Shah, N. Nora Bennani, Mrinal M. Patnaik, Grzegorz S. Nowakowski, Gita Thanarajasingam, Thomas M. Habermann, Robert Vassallo, Taimur Sher, Sameer A. Parikh, Karen L. Rech, Ronald S. Go, Mayo Clinic Histiocytosis Working Group

Haematologica Apr 2019, haematol.2019.219626; DOI: 10.3324/haematol.2019.219626
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
Richard T. Silver, Spencer Krichevsky

Haematologica Apr 2019, haematol.2018.213108; DOI: 10.3324/haematol.2018.213108
Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production
Araceli Tobío, Geethani Bandara, Denise A. Morris, Do-Kyun Kim, Michael P. O'Connell, Hirsh D. Komarow, Melody C. Carter, Daniel Smrz, Dean D. Metcalfe, Ana Olivera

Haematologica Apr 2019, haematol.2018.212126; DOI: 10.3324/haematol.2018.212126
Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy
Yasutaka Fukuda, Marito Araki, Kouji Yamamoto, Soji Morishita, Tadaaki Inano, Kyohei Misawa, Tomonori Ochiai, Yoko Edahiro, Misa Imai, Hajime Yasuda, Akihiko Gotoh, Akimichi Ohsaka, Norio Komatsu

Haematologica Apr 2019, haematol.2018.208876; DOI: 10.3324/haematol.2018.208876
Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
Anaïs Roeser, Fleur Cohen-Aubart, Paul Breillat, Makoto Miyara, Jean-François Emile, Frédéric Charlotte, Jean Donadieu, Zahir Amoura, Julien Haroche

Haematologica Mar 2019, haematol.2018.214007; DOI: 10.3324/haematol.2018.214007
SDF1α-induced chemotaxis of JAK2-V617F positive cells is dependent on Bruton's Tyrosine Kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA
Subbaiah Chary Nimmagadda, Stephanie Frey, Peter Müller, Denise Wolleschak, Söenke Weinert, Ulrich Keller, Bärbel Edelmann, Thomas Fischer

Haematologica Feb 2019, haematol.2018.201921; DOI: 10.3324/haematol.2018.201921
Quantitative dynamic 18F-FDG PET/CT before autologous stem cell transplantation predicts survival in multiple myeloma
Christos Sachpekidis, Maximilian Merz, Annette Kopp-Schneider, Anna Jauch, Marc-Steffen Raab, Sandra Sauer, Jens Hillengass, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss

Haematologica Feb 2019, haematol.2018.213041; DOI: 10.3324/haematol.2018.213041
Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age, a systematic review.
Jean-Christophe Ianotto, Natalia Curto-Garcia, Marie Lauermannova, Deepti Radia, Jean-Jacques Kiladjian, Claire N. Harrison

Haematologica Jan 2019, haematol.2018.200832; DOI: 10.3324/haematol.2018.200832
Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene epigenetically regulated
Nicolás Martínez-Calle, Marien Pascual, Raquel Ordoñez, Edurne San José-Enériz, Marta Kulis, Estíbaliz Miranda, Elisabeth Guruceaga, Víctor Segura, María José Larráyoz, Beatriz Bellosillo, María José Calasanz, Carles Besses, José Rifón, José I. Martín-Subero, Xabier Agirre, Felipe Prosper

Haematologica Jan 2019, haematol.2018.204917; DOI: 10.3324/haematol.2018.204917

More articles from Myeloproliferative Disorders

Pages